Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) Stock Gains Momentum: Is it Sustainable?

August 20, 2021

Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) jumped 4% no news. The company offered its corporate updates and financial results for Q2 2021. At the end of the quarter, the company had cash and equivalents of $33.1 million, which is adequate to support completing its clinical studies for its flagship treatment candidate Seclidemstat. CEO David Arthur said that the second quarter was a considerable development period for the company, shown by the significant…

Read More >>

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) Expands Study Sites For Seclidemstat Dose Expansion Trial

July 15, 2021

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) has announced the addition of Fox Chase Cancer Center in Philadelphia, Pennsylvania, as an active study site for the ongoing clinical trial dose-expansion phase. The company evaluates its flagship candidate, seclidemstat, to treat patients with advanced FET-rearranged and refractory or relapsed Ewing sarcomas.  Salarius to evaluate seclidemstat in Ewing sarcoma  Fox Chase’s addition expands the participating active trial site number to nine for the open-label…

Read More >>